Version May 2024
Allergic conjunctivitis: Ophthalmic: Instill 1 drop into the affected eye(s) twice daily.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
Allergic conjunctivitis: Ophthalmic: Children ≥2 years: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Gastrointestinal: Dysgeusia (25%)
1% to 10%:
Central nervous system: Headache (2% to 5%)
Ophthalmic: Eye irritation (2% to 5%)
Respiratory: Nasopharyngitis (2% to 5%)
<1%, postmarketing, and/or case reports: Hypersensitivity reaction, pharyngeal edema, pruritus, skin rash, swelling of lips, swollen tongue
Hypersensitivity to bepotastine or any component of the formulation
Special populations:
• Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 10 minutes before reinserting.
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lenses if eye is red.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as besilate:
Bepreve: 1.5% (5 mL, 10 mL) [contains benzalkonium chloride]
Generic: 1.5% (5 mL, 10 mL)
Yes
Solution (Bepotastine Besilate Ophthalmic)
1.5% (per mL): $52.13
Solution (Bepreve Ophthalmic)
1.5% (per mL): $69.06
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as besilate:
Bepreve: 1.5% (1 mL, 5 mL, 10 mL) [contains benzalkonium chloride]
For topical ophthalmic use only. Contact lenses should be removed prior to application, may be inserted after 10 minutes. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip.
Ophthalmic: For topical ophthalmic use only. Contact lenses should be removed prior to application, may be inserted after 10 minutes. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip.
Allergic conjunctivitis: Treatment of itching associated with allergic conjunctivitis
None known.
There are no known significant interactions.
Plasma concentrations are below the limits of detection 24 hours after ophthalmic use. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).
It is not known if bepotastine is present in breast milk following ophthalmic use; however, plasma concentrations are below the limits of detection 24 hours after instillation. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Direct H1-receptor antagonist and inhibits release of histamine from mast cells
Onset of action: Within 3 minutes (Macejko 2010)
Duration: Up to 16 hours (Williams 2011)
Absorption: Minimal systemic absorption
Protein binding: ~55%
Metabolism: Minimal via CYP enzymes
Time to peak, serum: 1 to 2 hours
Excretion: Urine (~75% to 90% unchanged)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
